GCA
REGN icon

Gideon Capital Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Gideon Capital Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-956
Closed -$359K – 443
2017
Q4 		$359K Buy
+956
New +$387K 0.32% 105
2017
Q3 		– Sell
-566
Closed -$278K – 362
2017
Q2 		$278K Buy
+566
New +$248K 0.31% 141

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Gideon Capital Advisors's REGN Position: Q1 2018 in Review

Gideon Capital Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q1 2018, closing a stake of 956 shares — an estimated $359K sold.

Gideon Capital Advisors first reported a position in REGN in Q2 2017 and held it in 2 quarters. The position peaked at $359K in Q4 2017. 619 funds tracked by Wall St. Rank hold REGN as of Q1 2018.

  • Gideon Capital Advisors reported no remaining Regeneron Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Gideon Capital Advisors sold 956 Regeneron Pharmaceuticals shares in Q1 2018, an estimated $359K.
  • Gideon Capital Advisors first reported a position in Regeneron Pharmaceuticals in Q2 2017 and held it in 2 quarters.
  • Gideon Capital Advisors's Regeneron Pharmaceuticals position peaked at $359K in Q4 2017.
  • 619 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2018.

Based on Gideon Capital Advisors's 13F filing for Q1 2018, filed 14 May 2018.